{"count": 1, "results": [{"_id": "23761972", "pmid": 23761972, "pmcid": "PMC3673969", "title": "Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin", "journal": "Vasc Health Risk Manag", "authors": ["Steinberg H", "Anderson MS", "Musliner T", "Hanson ME", "Engel SS"], "date": "2013-01-01T00:00:00Z", "doi": "10.2147/VHRM.S44330", "meta_date_publication": "2013", "meta_volume": "9", "meta_issue": "", "meta_pages": "273-82", "score": 50080.504, "text_hl": "Based on the available evidence regarding the pharmacokinetics and the efficacy and safety profiles of each component drug, the @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ FDC may provide a rational and well-tolerated approach to achieving better adherence to multiple-drug therapy and improved @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ lowering and glycemic control, with consequent reduction in cardiovascular risk, @<m>DISEASE_612623</m> @DISEASE_OMIM:612623 @@@diabetic microvascular disease@@@, and mortality in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@ for whom treatment with both compounds is appropriate.", "citations": {"NLM": "Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin Vasc Health Risk Manag. 2013;9():273-82. PMID: 23761972", "BibTeX": "@article{23761972, title={Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin}, author={Steinberg H and Anderson MS and Musliner T and Hanson ME and Engel SS}, journal={Vasc Health Risk Manag}, volume={9}, pages={273-82}}"}}]}